Dry AMD / Geographic Atrophy — Deal Benchmarks & Valuation
Market Analysis
Dry AMD / Geographic Atrophy is one of the most actively transacted indications in ophthalmology licensing. Phase 2 deals for dry amd / geographic atrophy carry a median total deal value of $3.2B, with upfront payments ranging from $376M to $975M. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones.
Milestone structures for dry amd / geographic atrophy deals allocate $506M to development milestones, $632M to regulatory milestones, and $1.4B to commercial milestones. Royalty rates range from 9.9% to 19.7% at the base tier, with tiered escalation reaching 13.9%-23.7% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for dry amd / geographic atrophy licensing?
What royalty rates are standard for dry amd / geographic atrophy deals?
How are dry amd / geographic atrophy deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.